Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FOBs Help Wanted: Waxman Appeals To Obama

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA should start approving follow-on biologics even in the absence of legislation, House committee chairman tells president in bid to increase his negotiating leverage.

You may also be interested in...



FOBs: White House Says 7 Years Of Exclusivity Is "Generous Compromise"

Rep. Henry Waxman, D-Calif., probably had a pretty good moment at his mailbox last week: he got a 1letter from the White House essentially endorsing his approach to follow-on biologics

FOBs: White House Says 7 Years Of Exclusivity Is "Generous Compromise"

Rep. Henry Waxman, D-Calif., probably had a pretty good moment at his mailbox last week: he got a 1letter from the White House essentially endorsing his approach to follow-on biologics

Follow-On Biologics: White House Calls 7 Years Of Exclusivity A "Generous Compromise"

Reply to Rep. Waxman notes that "a serious review of FDA's existing authorities is underway."

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel